ERCC1 plays an important role in predicting survival outcomes and treatment response for patients with HNSCC: A meta-analysis

Oral Oncology

Volumn 51, Issue 5, 2015, Pages 483-492

  Xuelei, Ma ^a   Jingwen, Huang ^a   Wei, Du ^a   Hongyu, Zhuo ^a   Jing, Zhang ^a   Changle, Shi ^a   Lei, Liu ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Chemoradiotherapy; Cisplatin; ERCC1; HNSCC; Meta analysis; Prognosis; Radiotherapy; Treatment response

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; BIOLOGICAL MARKER; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONFIDENCE INTERVAL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KAPLAN MEIER METHOD; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RACE; SURVIVAL RATE; TREATMENT RESPONSE; HEAD AND NECK TUMOR; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA; SURVIVAL; TREATMENT OUTCOME;

BIOMARKERS; CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; ENDONUCLEASES; HEAD AND NECK NEOPLASMS; HUMANS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84933674368     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2015.02.094     Document Type: Article

References (61)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90.
2. Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Curr Opin Oncol 2002;14(3):334-42.
3. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328(3):184-94.
4. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349(22):2091-8.
5. Tang C, Chan C, Jiang W, et al. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head Neck 2014.
6. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257-63.
7. Zaboli D, Tan M, Gogineni H, et al. Hyperfractionated radiotherapy with concurrent cisplatin/5-Fluorouracil for locoregional advanced head and neck cancer: analysis of 105 consecutive patients. Int J Otolaryngol 2012;2012:754191.
8. Nouspikel T. DNA repair in mammalian cells: so DNA repair really is that important. Cell Mol Life Sci 2009;66(6):965-7.
9. Su Y, Orelli B, Madireddy A, Niedernhofer LJ, Scharer OD. Multiple DNA binding domains mediate the function of the ERCC1-XPF protein in nucleotide excision repair. J Biol Chem 2012;287(26):21846-55.
10. Ahmad A, Robinson AR, Duensing A, et al. ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol 2008;28(16):5082-92.
11. McNeil EM, Melton DW. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucl Acids Res 2012;40(20):9990-10004.
12. Bai ZL, Wang YY, Zhe H, He JL, Hai P. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma. Radiat Oncol 2012;7:221.
13. Liu YP, Ling Y, Qi QF, et al. The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Oncol Lett 2013;5(3):935-42.
14. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127(3):978-83.
15. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356(8):800-8.
16. Torii Y, Kato R, Minami Y, Hasegawa K, Fujii T, Udagawa Y. ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells. Anticancer Res 2014;34(1):107-15.
17. Li W, Melton DW. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Oncogene 2012;31(19):2412-22.
18. Chiu TJ, Chen CH, Chien CY, Li SH, Tsai HT, Chen YJ. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. J Trans Med 2011;9:31.
19. Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L. Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 2011;37(7):427-34.
20. Kawashima A, Takayama H, Tsujimura A. A review of ERCC1 gene in bladder cancer: implications for carcinogenesis and resistance to chemoradiotherapy. Adv Urol 2012;2012:812398.
21. JPT Higgins SG. [PDF][PDF] Cochrane handbook for systematic reviews of interventions. The Cochrane Library; 2005.
22. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform metaanalyses of the published literature for survival endpoints. Stat Med 1998;17(24):2815-34.
23. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002;21(22):3337-51.
24. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
26. Bisof V, Jakovcevic A, Seiwerth S, Rakusic Z, Gasparov S. Prognostic value of ERCC1 in head and neck carcinoma treated with definitive or adjuvant radiotherapy. J Cancer Res Clin Oncol 2013;139(2):187-94.
27. Handra-Luca A, Hernandez J, Mountzios G, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007;13(13):3855-9.
28. Hao D, Lau HY, Eliasziw M, et al. Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status. Head Neck 2012;34(6):785-91.
29. Jun. HJ, Ahn MJ, Kim HS, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 2008;99(1):167-72.
30. Park Y, Kim DS, Park KH, et al. RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. Onkologie 2012;35(11):673-82.
31. De Castro G, Jr Pasini FS, Siqueira SA, et al. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Oncol Rep 2011;25(3):693-9.
32. Fountzilas G, Bamias A, Kalogera-Fountzila A, et al. Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. Anticancer Res 2009;29(2):529-38.
33. Hayes M, Lan C, Yan J, et al. ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res 2011;31(12):4135-9.
34. Patel MR, Zhao N, Ang MK, et al. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2013;149(4):587-95.
35. Huang PY, Li Y, Mai HQ, Luo RZ, Cai YC, Zhang L. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Oral Oncol 2012;48(10):964-8.
36. Choi IJ, Kim DW, Kim DY, Lee CH, Rhee CS. Predictive markers for neoadjuvant chemotherapy in advanced squamous cell carcinoma of maxillary sinus: preliminary report. Acta Otolaryngol 2013;133(3):291-6.
37. Lee HW, Hwang YH, Han JH, et al. High expression of excision repair crosscomplementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer. Oral Oncol 2010;46(3):209-13.
38. Jagdis A, Phan T, Klimowicz AC, et al. Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment. Int J Radiat Oncol Biol Phys 2013;85(5):1340-5.
39. Sun JM, Ahn MJ, Park MJ, et al. Expression of excision repair crosscomplementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2011;80(3):655-60.
40. Krikelis D, Bobos M, Karayannopoulou G, et al. Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. BMC Clin Pathol 2013;13:1.
41. Bauman JE, Austin MC, Schmidt R, et al. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer 2013;109(8):2096-105.
42. Saijo N, Fukuoka M, Thongprasert S, et al. Lung cancer working group report. Jpn J Clin Oncol 2010;40(Suppl 1):i7-i12.
43. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25(19):2747-54.
44. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in nonsmall cell lung cancer. Clin Cancer Res 2002;8(7):2286-91.
45. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatinbased chemotherapy. Ann Oncol 2007;18(3):522-8.
46. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94(2):703-8.
47. Mladenov E, Magin S, Soni A, Iliakis G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol 2013;3:113.
48. Ravanat JL, Breton J, Douki T, et al. Radiation-mediated formation of complex damage to DNA: a chemical aspect overview. Br J Radiol 2014;1035(87):20130715.
49. Havaki S, Kotsinas A, Chronopoulos E, Kletsas D, Georgakilas A, Gorgoulis VG. The role of oxidative DNA damage in radiation induced bystander effect. Cancer Lett 2014.
50. Stordal B, Davey M. Understanding cisplatin resistance using cellular models. IUBMB Life 2007;59(11):696-9.
51. Usanova S, Piee-Staffa A, Sied U, et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 2010;9:248.
52. Al-Minawi AZ, Lee YF, Hakansson D, et al. The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucl Acids Res 2009;37(19):6400-13.
53. Lindsey-Boltz LA, Kemp MG, Reardon JT, et al. Coupling of human DNA excision repair and the DNA damage checkpoint in a defined in vitro system. J Biol Chem 2014;289(8):5074-82.
54. Marini F, Nardo T, Giannattasio M, et al. DNA nucleotide excision repairdependent signaling to checkpoint activation. Proc Nat Acad Sci U S A 2006;103(46):17325-30.
55. Yang J, Liu X, Niu P, et al. Dynamic changes of XPA, XPC, XPF, XPG and ERCC1 protein expression and their correlations with levels of DNA damage in human bronchial epithelia cells exposed to benzo [a]pyrene. Toxicol Lett 2007;174(1-3):10-7.
56. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355(10):983-91.
57. Smit EF, Socinski MA, Mullaney BP, et al. Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. Ann Oncol 2012;23(7):1723-9.
58. Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014;32(18):1889-94.
59. Wislez M, Barlesi F, Besse B, et al. Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. J Clin Oncol 2014;32(12):1256-61.
60. Tsodikov OV, Enzlin JH, Scharer OD, Ellenberger T. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1. Proc Natl Acad Sci U S A 2005;102(32):11236-41.
61. Tripsianes K, Folkers G, Ab E, et al. The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure 2005;13(12):1849-58.